Pfizer, Astellas' Xtandi matches J&J's rival Erleada with new prostate cancer nod

Pfizer and Astellas' stalwart prostate cancer med Xtandi has watched as Johnson & Johnson's challenger, Erleada, picked up the lead in the metastatic, castration-sensitive form of the disease. But now Xtandi is ready to take on its familiar foe with a new green light of its own, which the FDA granted on Monday.